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Abstract 
A 7 year old female spayed Hovawart dog presented to the Cornell University 
Hospital for Animal’s Oncology service for further treatment options of a previously 
excised cutaneous malignant melanoma.  Four months prior to presentation, the owners 
noted a small, black raised mass over the dog’s left lumbar region.  The mass appeared to 
double in size over the next 3 weeks, and was surgical excised by the referring 
veterinarian.  The margins of the excision at this time were found to be approximately 1-2 
mm and the biopsy revealed malignant melanoma with approximately 40 mitosis per 10 
high-powered fields (HPF).  A scar revision surgery was performed by Cornell 
University Hospital for Animal’s Soft tissue surgery service on without complications.    
Although melanoma of the haired skin is often benign, this dog's tumor had 
several criteria of malignancy, which often corresponds with a high metastatic rate.  Due 
to the risk of metastasis, the Oncology service offered systemic therapy and the owner 
decided on the melanoma vaccine.  Diagnosis, treatment options, and prognosis of 
cutaneous melanoma, along with the use of the melanoma vaccine to prolong survival for 
malignant melanoma will be discussed below. 
 
Case history 
A 7 year old female spayed Hovawart dog presented to the Cornell University 
Hospital for Animal’s Oncology service for further treatment options of a previously 
excised cutaneous malignant melanoma.  The owner’s noted a black, raised mass over the 
dogs left lumbar region four months prior to presentation.  An aspirate was performed at 
this time at the referring veterinarian; however the cytology results were inconclusive. 	 2
The dog had no clinical signs other than the mass, and no previous medical history.  The 
dog competed in agility and was used as a therapy dog at libraries and hospitals.    
The owners monitored the mass and one month prior to presentation to Cornell, it 
appeared to double in size over a period of 3 weeks.  The mass was surgically excised by 
the referring veterinarian.  At this time, a small cutaneous mass was also removed from 
the right side of the dog’s chest.  The subcutaneous mass on the right side of the chest 
was found to be cystic in nature, however this was not submitted for histopathology.  The 
excised mass over the left lumbar region was submitted for histopathology and the 
margins of the excision at this time were found to be approximately 1-2 mm and the 
biopsy revealed malignant melanoma, with approximately 40 mitosis per 10 HPF.  
 
Physical Exam 
On presentation to Cornell University’s Hospital for Animal’s Oncology service 
the dog presented for additional treatment options.  Physical examination revealed, the 
dog was bright, alert, and responsive and her vital parameters were within normal limits 
(T = 102.2 F, P = 140 bpm, RR = 42 brpm).   There was a small area that was clipped 
over the dorsal left flank where the mass excision occurred 2 weeks ago.  The incision 
was approximately 4 cm in length and the epidermis was well apposed, non-absorbable 
sutures were intact, and no heat, mucopurulent discharge, or inflammation was present.  
Another area was clipped over the right side of the dog’s chest, where a cyst had been 
removed.  The incision was small, contained no sutures, the epidermis was apposed, and 
no inflammation, discharge, or heat was present at the site.  The remainder of the physical 
exam was within normal limits.   	 3
 
Diagnostic Tests 
  The initial work-up for the dog included a complete blood count, chemistry, 
urinalysis, abdominal ultrasound, and three-view thoracic radiographs.  The complete 
blood count, chemistry, and urinalysis were performed to obtain a baseline health status 
on the dog, and the results were within normal limits.   Thoracic radiographs and 
abdominal ultrasound were performed to search for evidence of metastasis.  The three-
view radiographs were clinically normal and negative for metastasis.  The abdominal 
ultrasound revealed a diffusely, mildly enlarged spleen with normal echogenicity.  Based 
on these findings, there was no strong evidence of metastasis and overall the dog 
appeared to be in good health. 
 
Problem List/Differential Diagnosis 
The problems identified based on history, physical examination, and diagnostic 
testing include a previous malignant cutaneous melanoma and diffuse, mild 
splenomegaly.  The differential diagnosis for a pigmented cutaneous mass include; 
benign melanocytoma, melanocytic hyperplasia, hemangioma, hemangiosarcoma, basal 
cell tumor, or histiocytic sarcoma (Smith, 2002). 
The differential diagnosis for diffuse, mild splenomegaly includes; normal breed 
variation, effects of sedation, mild congestion, or diffuse infiltration (due to inflammation 
or neoplasia such as lymphoma).  Since this dog was sedated for imaging to be 
performed, it was likely the effects of sedation causing diffuse splenomegaly. 
 	 4
Procedures and Treatment 
A consult with the Cornell University Hospital for Animal’s Soft tissue surgery 
service was performed.  The soft tissue service decided that a scar revision surgery would 
be possible over the dog’s left lumbar region.  This surgery would ensure adequate 
margins and excision of any remaining neoplastic cells.  A scar revision surgery was 
performed by Cornell University Hospital for Animal’s Soft tissue surgery service the 
following week.  A	9 x 5 cm elliptical skin incision around the pre-existing scar was 
made over the left lateral lumbar region using a #15 blade.  The incision was extended 
down to include the dorsal edge of the external abdominal oblique superficial fascia by 
blunt dissection.  The tissue removed was submitted for histopathology. The results of the 
histopathology performed by Cornell University Anatomic Pathology laboratory revealed 
no evidence of neoplastic cells, and only scar tissue and inflammation was present.  This 
implies complete excision was achieved.     
The slides from the original mass excision performed by the referring 
veterinarian, were submitted to the Cornell University Anatomic Pathology laboratory for 
review.  The slide review found a highly cellular tissue with cells arranged in bundles and 
streams, similar to mesenchymal tissue.  Some cells had pigment present and there were 
approximately 40 mitosis per 10 HPF.   Immunohistochemistry using both Melan A and 
S100, revealed diffusely neoplastic cells with moderate to strong positive granular 
cytoplasmic staining.    
Complete excision of the scar was achieved with no evidence of neoplastic cells.  
This likely implies that clean margins were obtained around the dog’s malignant 
melanoma, however there is always the possibility for error when evaluating margins.  	 5
The original findings on histopathology imply that the mass was a highly malignant 
melanoma with an aggressive mitotic rate of 40 mitosis per 10 HPF.  Treatment of 
malignant melanomas involves both local control (with surgery) and systemic therapy to 
address the potential metastatic disease. Due to the high chance of metastasis, additional 
systemic therapy was offered for this dog and the owner elected to treat with the 
melanoma vaccine. 
 
Discussion 
The most common locations for melanoma to occur include the oral cavity, digit, 
and haired skin.  Cutaneous melanoma is one of the most common skin tumors in dogs, 
consisting of approximately 5-7% of skin tumors and is most commonly benign 
(Withrow, 2007). Cutaneous melanoma occurs more commonly in dogs with heavily 
pigmented skin.  Predisposed breeds include Boston terriers, Boxers, Chow chow, Cocker 
spaniels, Dobermans, Golden Retrievers, Scottish terriers (Morrison, 1998).  The exact 
etiology of cutaneous melanoma is unknown, however ionizing sunlight does not appear 
to be a causative factor like it is in humans (Withrow, 2007).   
Location is a very important prognostic indicator for melanoma.  Approximately 
80% of tumors of the haired skin are benign and 20% are malignant.  As demonstrated in 
the case described above, location should not be the only factor used to determine 
behavior.  A combination of clinical findings and morphologic features such as nuclear 
atypia and mitotic index should be used to predict behavior (Smedley, 2011).  Benign 
melanomas tend to be well defined, less than 2 centimeters, deeply pigmented, firm but 
mobile over underlying tissues, and have a mitotic index of less than 3 per 10 HPF.  	 6
Malignant melanomas tend to grow rapidly, extend into underlying tissues, be greater 
than 2 centimeters, ulcerated, and have a mitotic index greater than 3 per 10 HPF. 
Prognosis for malignant melanomas is guarded because 30-75% metastasize. The 
most common locations for metastasis include regional lymph nodes, lungs, and rarely 
the brain, heart, or spleen.  Unfortunately, most dogs with malignant disease will 
eventually succumb to metastatic disease (Withrow, 2007).  
The treatment of choice for malignant melanoma is surgical excision with wide 
margins.  Radiation therapy, chemotherapy, and the melanoma vaccine have also been 
used as adjunctive therapy.  Radiation therapy is not successful in areas of bulky disease 
and therefore is generally used for incomplete tumor excision or lymph node metastasis.  
Unfortunately, even when used on small tumors or lymph nodes, radiation therapy tends 
to have short-lived effects and complete response rates are relatively low ranging from 
53% -69%.  Chemotherapy has also been shown to have short-lived effects and low 
response rates.  One study found Carboplatin to have about a 28% response rate, while 
Cisplatin and Piroxicam have been shown to have an 18% response rate (Bergman, 
2008). 
The melanoma vaccine is a xenogeneic tyrosinase DNA vaccine that was FDA 
approved in December 2009.  Tyrosinase is the rate-limiting enzyme in the production of 
melanin.  There is only a 9% difference between human and canine tyrosinase DNA.  The 
immune response generated against the human DNA is similar enough to attack self-
tumor cells (Bergman, 2003).  An immune response begins approximately 6 weeks after 
initial vaccination and reaches its highest levels around eleven months (Liao, 2007).  
Approximately 8,000 dogs have received this vaccine to date and minimal side effects 	 7
have been seen.  Side effects include mild local reactions such as pain, erythema, or 
short-term lameness.  Autoimmune depigmentation has also been observed in localized 
regions such as the pinna or foot pad, however this is a rare side effect (Bergman, 2008). 
The true efficacy of the vaccine is not well known. There are no studies involving 
cutaneous malignant melanoma and treatment with the melanoma vaccine.  Studies do 
support that there is some improvement in survival with the vaccine when compared to 
surgery alone for oral and digit melanoma.  One study involving dogs diagnosed with 
oral melanoma show a median survival time with conventional therapy to be 
approximately 30-150 days versus 389 days for treatment with the melanoma vaccine 
(Bergman, 2003).  A study involving melanoma of the digit showed amputation alone 
had a median survival time of 365 days versus treatment with amputation and the 
melanoma vaccine to be 467 days (Manley, 2011). 
 
Outcome 
In this case, the dog was treated with the FDA approved human tyrosinase DNA 
vaccine (Bergman, 2003).  The dog received four initial immunizations two weeks apart 
followed by boosters every 6 months.  Three-view thoracic radiographs were performed 
prior to each 6 month booster to check for evidence of metastatic disease. At the last 
recheck appointment (her second booster), she had no clinical signs or regrowth of the 
mass, and her three view thoracic radiographs were negative for metastasis. 
 
Conclusion 	 8
This case of cutaneous malignant melanoma in the dog, demonstrates that 
although location is a critical factor in predicting behavior of melanomas, many other 
features should be examined.  Surgical excision with wide margins is the treatment of 
choice for malignant melanomas, however systemic therapy should also be considered 
due to the high rate of metastatic disease (Withrow, 2007). 
Enhancing immunosurveillance against tumor cells by vaccination is a useful and 
safe therapy.  The success of the melanoma DNA vaccine can be used as a model for 
other cancers such as Lymphoma, Canine Osteosarcoma, and Feline Mammary 
Adenocarcinoma (Bergman, 2008).  Advancements in research may find that xenogeneic 
DNA vaccines can play an important role in systemic cancer therapy. 
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